Glioblastoma (GBM) Clinical Trials

18 recruiting

Frequently Asked Questions

Common questions about Glioblastoma (GBM) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 118 of 18 trials

Recruiting
Phase 2

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Central Nervous System DiseasesBrain CancerGlioblastoma Multiforme (GBM)+4 more
Black Diamond Therapeutics, Inc.162 enrolled1 locationNCT07326566
Recruiting
Phase 3

Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma

GlioblastomaNeoplastic DiseaseGlioblastoma (GBM)+3 more
Telix Pharmaceuticals (Innovations) Pty Limited50 enrolled4 locationsNCT07100730
Recruiting
Not Applicable

UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-4

Glioblastoma (GBM)Astrocytoma, Grade IV
Sunnybrook Health Sciences Centre60 enrolled1 locationNCT07459101
Recruiting
Early Phase 1

A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases

Brain MetastasasesGlioblastoma (GBM)
Nader Sanai15 enrolled1 locationNCT07268053
Recruiting
Phase 2

DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

Glioblastoma (GBM)
Diakonos Oncology Corporation180 enrolled13 locationsNCT06805305
Recruiting

Clinical Significance of Liquid Biopsy in Brain Tumor Patients: a 5-ALA Guided Approach

GlioblastomaGlioblastoma (GBM)Glioblastoma - Category+1 more
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta30 enrolled1 locationNCT07420543
Recruiting
Phase 1

A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma

Glioblastoma (GBM)Newly Diagnosed Glioblastoma Multiforme
CHA University10 enrolled1 locationNCT07143812
Recruiting
Phase 1

Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated Glioblastoma

Glioblastoma (GBM)
University of Virginia12 enrolled1 locationNCT07343986
Recruiting

The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling

Colorectal, CancerOvarian CancerBrest Cancer+5 more
Javier Toledo6,000 enrolled4 locationsNCT06717295
Recruiting
Phase 1Phase 2

Clinical Study of Oncolytic Virus in Glioblastoma

Glioblastoma (GBM)
Mianyang Central Hospital20 enrolled1 locationNCT07145047
Recruiting
Not Applicable

The Feasibility and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the Treatment of Glioblastoma

Glioblastoma (GBM)IDH Wildtype Glioblastoma
Ottawa Hospital Research Institute50 enrolled2 locationsNCT06850766
Recruiting
Phase 2

Stupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread

Glioblastoma (GBM)
Second Affiliated Hospital, School of Medicine, Zhejiang University38 enrolled1 locationNCT07193654
Recruiting
Phase 2

G-CSF After Chemo-radiation in Patients With Glioblastoma

Glioblastoma (GBM)MGMT-Methylated GlioblastomaNewly Diagnosed Glioblastoma Multiforme
Massachusetts General Hospital60 enrolled1 locationNCT06649851
Recruiting
Phase 2

Enhanced Local Intensified Radiation Therapy in Elderly Glioblastoma: A Phase 2 Hybrid Randomized Trial

Glioblastoma (GBM)
Brigham and Women's Hospital56 enrolled3 locationsNCT06835803
Recruiting
Not Applicable

FearLess in NeuroOncology

CaregiverGlioblastoma (GBM)Oligodendroglioma+2 more
Virginia Commonwealth University112 enrolled1 locationNCT06989086
Recruiting
Not Applicable

Allogeneic γδT Cells in Glioblastoma

Glioblastoma Multiforme (GBM)Glioblastoma (GBM)
Peking University Third Hospital18 enrolled3 locationsNCT07144735
Recruiting
Not Applicable

Advanced Diffusion MRI to Differentiate Tumor Recurrence From Pseudoprogression in Patients With Glioblastoma and Brain Metastases

Glioblastoma (GBM)
University Hospital, Basel, Switzerland10 enrolled1 locationNCT05911230
Recruiting
Early Phase 1

Safety and Efficacy of NRG-103 Injection in the Treatment of Recurrent Glioblastoma Patients

Glioblastoma (GBM)
Zhongnan Hospital15 enrolled1 locationNCT06757153